Radiation therapy treatment for breast cancer not only improves survival rates but also generates long-term financial ...
Cells are regularly faced with environmental stresses that may damage or destroy them. To survive, they quickly adjust their gene expression to protect themselves.
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for ...
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® ...
As the ketogenic diet becomes more popular, new studies warn of potential long-term risks-from liver dysfunction and ...
Researchers have developed a molecule called SU212 that could revolutionize treatment for triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease.
The study sought to answer questions about how breast cancer risk differs by type of hormonal contraceptive. Doctors say the ...
Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...
The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer. FDA ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Experts share when and how to perform a breast self-exam while breastfeeding and when to elevate any concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback